查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1615418

非专利药注射剂市场：按产品、类型、给药途径、容器、应用、分销管道 - 2025-2030 年全球预测

Generic Injectables Market by Product (Large Molecule Injectables, Small Molecule Injectables), Type (Blood Factors, Chemotherapy Agents, Cytokines), Route of Administration, Container, Application, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年非专利药注射剂市值为331.2亿美元，预计到2024年将达到365.8亿美元，复合年增长率为10.64%，到2030年将达到672.2亿美元。

非专利注射剂市场包括与品牌注射剂具有生物等效性但以其通用名称销售的药物。这些产品由于其成本效益、基本药物的可近性以及对降低医疗保健成本的贡献，对世界各地的医院、诊所和门诊病人设施至关重要。医疗保健系统不断寻找适应预算紧缩的方法，而非专利注射剂的使用在实现这一目标方面发挥着重要作用。该市场的一个关键成长动力是糖尿病和癌症等慢性疾病的日益流行，这些疾病需要频繁使用注射药物进行治疗。此外，监管环境，特别是专利悬崖形式的支持，为市场扩张提供了有利条件。然而，潜在的挑战包括严格的监管核准流程、定价压力和製造复杂性，这些可能会阻碍快速进入市场。进一步的限制包括与供应链中断相关的问题以及与製造品质标准相关的高成本。然而，新兴市场的需求有机会成长，这些市场的医疗基础设施正在发展，获得负担得起的药品正成为首要任务。公司可以透过投资本地製造单位和合作伙伴来利用这一趋势。专注于药物输送系统的创新，例如无针注射器和预填充式注射器，可以提高患者的依从性并开拓新的消费群体。生技药品和生物相似药也因其以低成本提供复杂治疗方法的潜力而成为一个有前途的创新领域。由于市场竞争激烈，且拥有大量大大小小的製药公司，因此策略重点放在研发以及与医疗保健提供者合作可以推动业务成长。总体而言，推动更永续的医疗保健解决方案强调了推广非专利注射剂并继续成为全球健康策略不可或缺的一部分的必要性。

主要市场统计
基准年[2023] 331.2亿美元
预计年份 [2024] 365.8亿美元
预测年份 [2030] 672.2亿美元
复合年增长率（%） 10.64%

市场动态：揭示快速发展的非专利注射剂市场的关键市场洞察

供需的动态交互作用正在改变非专利药注射药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 慢性病流行和对具有成本效益的药物的需求
    • 专利到期增加并强调采用学名药
    • 政府对学名药和注射剂的有利核准
  • 市场限制因素
    • 病人和医生对品牌药物的偏好
  • 市场机会
    • 正在进行的与非专利注射药物相关的研究和开发活动
    • 建立非专利注射剂生产的长期策略伙伴关係
  • 市场挑战
    • 对注射品质和製造差异的担忧

波特五力：驾驭非专利药注射药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解非专利药注射药物市场的外部影响

外部宏观环境因素在塑造非专利注射剂市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解非专利注射剂市场的竞争状况

对非专利药注射剂市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 在仿製药市场中的定位非专利供应商绩效评估

FPNV定位矩阵是评估非专利注射剂市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，规划非专利注射剂市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对非专利注射剂市场进行策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病的流行和对具有成本效益的药物的需求
      • 专利到期增加并重视引进学名药
      • 政府对学名药和注射剂的有利核准
    • 抑制因素
      • 病人和医生对品牌药物的偏好
    • 机会
      • 正在进行的与非专利注射药物相关的研究和开发活动
      • 生产非专利注射剂的长期策略伙伴关係
    • 任务
      • 对注射品质和製造差异的担忧
  • 市场区隔分析
    • 产品：由于可用性和熟悉度，各个治疗领域小分子注射剂的消费量增加
    • 类型：非专利药市场探索蓬勃发展的经济中的动态成长
    • 应用：非专利药注射剂在心臟病学和肿瘤学领域的显着优势需要长期且永续的药物成本
    • 分销管道：网路商店因其便利性和有竞争力的价格而越来越受欢迎。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章非专利药注射剂市场：副产品

  • 聚合物注射
  • 低分子注射液

第七章非专利药注射剂市场：按类型

  • 血液因素
  • 化疗剂
  • 细胞激素
  • 胰岛素
  • 单株抗体
  • 胜肽类抗生素
  • 肽激素
  • 疫苗

第八章非专利药注射剂市场：依给药途径分类

  • 肌肉注射 (IM)
  • 静脉注射 (IV)
  • 皮下注射（SC）

第九章非专利药市场：依容器分类

  • 安瓿
  • 预填充式注射器
  • 预混合料
  • 管瓶

第10章非专利药注射剂市场：依应用分类

  • 血液疾病
  • 心臟病学
  • 糖尿病
  • 荷尔蒙失调
  • 免疫学
  • 肿瘤学
  • 疼痛管理

第十一章非专利药注射剂市场：按分销管道

  • 医院药房
  • 网上处方笺商店
  • 零售药房

第十二章美洲非专利药注射剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十三章亚太地区非专利药注射剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十四章 欧洲、中东和非洲非专利注射剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Cooper Consumer Health 收购 Viatris 的 OTC 业务
    • Teva 推出 FDA核准的廉价学名药Victoza，以改善糖尿病治疗的可及性
    • Lupin 推出 FDA核准的醋酸加尼瑞克注射液
    • Mayseal Pharmaceuticals 宣布扩大非专利药注射产品组合
    • 远藤公司推出诺沙非（Posaconazole）注射液的首个非专利药
  • 战略分析和建议

公司名单

  • Amgen Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Biocon Limited
  • Biological E. Limited
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Endo, Inc.
  • Fresenius Kabi AG
  • Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Meitheal Pharmaceuticals, Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Samsung Biologics Co., Ltd.
  • Sanofi SA
  • Somerset Pharma, LLC by Mylan
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc. by Cooper Consumer Health
Product Code: MRR-C002B1C997E0

The Generic Injectables Market was valued at USD 33.12 billion in 2023, expected to reach USD 36.58 billion in 2024, and is projected to grow at a CAGR of 10.64%, to USD 67.22 billion by 2030.

The market for generic injectables encompasses pharmaceutical products that are bioequivalent to branded injectables but are sold under their generic names. These products are critical due to their cost-effectiveness, access to essential medications, and contribution to reduced healthcare expenditure, making them essential for hospitals, clinics, and outpatient facilities globally. Health systems relentlessly seek ways to adapt to tightening budgets, and the utilization of generic injectables plays a crucial role in achieving this goal. A significant growth driver in this market is the increasing prevalence of chronic diseases, such as diabetes and cancer, which necessitates frequent use of injectables for treatment. Additionally, regulatory support, particularly in the form of patent cliff opportunities, provides a favorable landscape for market expansion. However, potential challenges include stringent regulatory approval processes, pricing pressures, and manufacturing complexities, which can impede rapid market entry. Furthermore, issues regarding supply chain disruptions and the high costs associated with production quality standards pose limitations. Nonetheless, opportunities arise from the growing demand in emerging markets, where healthcare infrastructure is developing and access to affordable medication is becoming a high priority. Companies can capitalize on this trend by investing in localized manufacturing units and collaborations. Innovations focusing on drug delivery systems-such as needle-free injectables or pre-filled syringes-can enhance patient compliance and open new consumer segments. Biologics and biosimilars are also emerging as promising areas for innovation due to their potential to offer complex therapies at lower costs. As the market is highly competitive, characterized by numerous small and large pharmaceutical companies, maintaining a strategic focus on R&D and forming alliances with healthcare providers can facilitate business growth. Overall, the push for more sustainable healthcare solutions underscores the imperative of advancing generic injectables, ensuring they remain integral in global health strategies.

KEY MARKET STATISTICS
Base Year [2023] USD 33.12 billion
Estimated Year [2024] USD 36.58 billion
Forecast Year [2030] USD 67.22 billion
CAGR (%) 10.64%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Generic Injectables Market

The Generic Injectables Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of chronic diseases and need for cost-effective medications
    • Increasing patent expirations and emphasis on adopting generic drugs
    • Favorable government approvals for generic drugs & injectables
  • Market Restraints
    • Preference for branded drugs by patients and physicians
  • Market Opportunities
    • Ongoing R&D activities associated with generic injectable drugs
    • Strategic long-term partnerships to manufacture generic injectables
  • Market Challenges
    • Concerns associated with injectable quality and manufacturing variability

Porter's Five Forces: A Strategic Tool for Navigating the Generic Injectables Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Generic Injectables Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Generic Injectables Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Generic Injectables Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Generic Injectables Market

A detailed market share analysis in the Generic Injectables Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Generic Injectables Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Generic Injectables Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Generic Injectables Market

A strategic analysis of the Generic Injectables Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Generic Injectables Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Baxter International Inc., Biocon Limited, Biological E. Limited, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo, Inc., Fresenius Kabi AG, Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Lupin Limited, Meitheal Pharmaceuticals, Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Samsung Biologics Co., Ltd., Sanofi S.A., Somerset Pharma, LLC by Mylan, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. by Cooper Consumer Health.

Market Segmentation & Coverage

This research report categorizes the Generic Injectables Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Large Molecule Injectables and Small Molecule Injectables.
  • Based on Type, market is studied across Blood Factors, Chemotherapy Agents, Cytokines, Insulin, Monoclonal Antibodies, Peptide Antibiotics, Peptide Hormones, and Vaccines.
  • Based on Route of Administration, market is studied across Intramuscular (IM), Intravenous (IV), and Subcutaneous (SC).
  • Based on Container, market is studied across Ampoules, Prefilled Syringes, Premix, and Vials.
  • Based on Application, market is studied across Blood Disorders, Cardiology, Diabetes, Hormonal Disorders, Immunology, Oncology, and Pain Management.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Prescription Stores, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and need for cost-effective medications
      • 5.1.1.2. Increasing patent expirations and emphasis on adopting generic drugs
      • 5.1.1.3. Favorable government approvals for generic drugs & injectables
    • 5.1.2. Restraints
      • 5.1.2.1. Preference for branded drugs by patients and physicians
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities associated with generic injectable drugs
      • 5.1.3.2. Strategic long-term partnerships to manufacture generic injectables
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with injectable quality and manufacturing variability
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Growing consumption of small molecule injectables in various therapeutic areas owing to their accessibility and familiarity
    • 5.2.2. Type: Exploring the dynamic growth in the booming generic injectables market
    • 5.2.3. Application: Significant benefits of generic injectables in cardiology and oncology, requiring long-term and sustainable medication costs
    • 5.2.4. Distribution Channel: Inclining preferences for online stores offering convenience and competitive pricing
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Generic Injectables Market, by Product

  • 6.1. Introduction
  • 6.2. Large Molecule Injectables
  • 6.3. Small Molecule Injectables

7. Generic Injectables Market, by Type

  • 7.1. Introduction
  • 7.2. Blood Factors
  • 7.3. Chemotherapy Agents
  • 7.4. Cytokines
  • 7.5. Insulin
  • 7.6. Monoclonal Antibodies
  • 7.7. Peptide Antibiotics
  • 7.8. Peptide Hormones
  • 7.9. Vaccines

8. Generic Injectables Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intramuscular (IM)
  • 8.3. Intravenous (IV)
  • 8.4. Subcutaneous (SC)

9. Generic Injectables Market, by Container

  • 9.1. Introduction
  • 9.2. Ampoules
  • 9.3. Prefilled Syringes
  • 9.4. Premix
  • 9.5. Vials

10. Generic Injectables Market, by Application

  • 10.1. Introduction
  • 10.2. Blood Disorders
  • 10.3. Cardiology
  • 10.4. Diabetes
  • 10.5. Hormonal Disorders
  • 10.6. Immunology
  • 10.7. Oncology
  • 10.8. Pain Management

11. Generic Injectables Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacy
  • 11.3. Online Prescription Stores
  • 11.4. Retail Pharmacy

12. Americas Generic Injectables Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Generic Injectables Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Generic Injectables Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Cooper Consumer Health's acquisition of Viatris Inc.'s OTC business
    • 15.3.2. Teva launches affordable FDA-approved generic Victoza boosting diabetes care access
    • 15.3.3. Lupin launches FDA-approved Ganirelix Acetate Injection
    • 15.3.4. Meitheal Pharmaceuticals Announces Expansion of Portfolio of Generic Injectable Products
    • 15.3.5. Endo Launches First Generic Version of Noxafil (posaconazole) Injection
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. AstraZeneca PLC
  • 3. Aurobindo Pharma Limited
  • 4. Baxter International Inc.
  • 5. Biocon Limited
  • 6. Biological E. Limited
  • 7. Bristol-Myers Squibb Company
  • 8. Cipla Limited
  • 9. Dr. Reddy's Laboratories Ltd.
  • 10. Endo, Inc.
  • 11. Fresenius Kabi AG
  • 12. Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd.
  • 13. GlaxoSmithKline PLC
  • 14. Hikma Pharmaceuticals PLC
  • 15. Johnson & Johnson Services, Inc.
  • 16. Lupin Limited
  • 17. Meitheal Pharmaceuticals, Inc.
  • 18. Merck & Co. Inc.
  • 19. Novartis AG
  • 20. Novo Nordisk A/S
  • 21. Pfizer Inc.
  • 22. Samsung Biologics Co., Ltd.
  • 23. Sanofi S.A.
  • 24. Somerset Pharma, LLC by Mylan
  • 25. Sun Pharmaceutical Industries Ltd.
  • 26. Teva Pharmaceutical Industries Ltd.
  • 27. Viatris Inc. by Cooper Consumer Health

LIST OF FIGURES

  • FIGURE 1. GENERIC INJECTABLES MARKET RESEARCH PROCESS
  • FIGURE 2. GENERIC INJECTABLES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENERIC INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. GENERIC INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. GENERIC INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENERIC INJECTABLES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENERIC INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENERIC INJECTABLES MARKET DYNAMICS
  • TABLE 7. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY LARGE MOLECULE INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY SMALL MOLECULE INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY BLOOD FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PEPTIDE ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PEPTIDE HORMONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY INTRAMUSCULAR (IM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY SUBCUTANEOUS (SC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY AMPOULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PREMIX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY VIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONLINE PRESCRIPTION STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. JAPAN GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 113. JAPAN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. JAPAN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 119. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 125. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 131. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 137. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 143. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. THAILAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. THAILAND GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. THAILAND GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 149. THAILAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. THAILAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 155. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. DENMARK GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. DENMARK GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. DENMARK GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 168. DENMARK GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. DENMARK GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. EGYPT GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. EGYPT GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. EGYPT GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 174. EGYPT GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. EGYPT GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. FINLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. FINLAND GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. FINLAND GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 180. FINLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. FINLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. FRANCE GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. FRANCE GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. FRANCE GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 186. FRANCE GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. FRANCE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. GERMANY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. GERMANY GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. GERMANY GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 192. GERMANY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. GERMANY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 195. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 198. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 201. ITALY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. ITALY GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. ITALY GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 204. ITALY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. ITALY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 210. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 216. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 219. NORWAY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. NORWAY GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. NORWAY GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 222. NORWAY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. NORWAY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 225. POLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. POLAND GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. POLAND GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 228. POLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. POLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 231. QATAR GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. QATAR GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. QATAR GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 234. QATAR GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. QATAR GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 239. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 240. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 246. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 252. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 255. SPAIN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. SPAIN GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. SPAIN GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 258. SPAIN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. SPAIN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 261. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 264. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 270. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 273. TURKEY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. TURKEY GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 275. TURKEY GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 276. TURKEY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. TURKEY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 288. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 290. GENERIC INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 291. GENERIC INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023